Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series: World’s leading Event Organizer
Cancer is a disease of misregulated genes, proteins, metabolites, cells, and biophysical forces. Early-stage cancers are difficult to diagnose and characterize, and late-stage cancers are invariably hard to treat. Clinically, cancer is an enormous burden on human health and society. The challenges span multiple spatiotemporal scales and will require engineering approaches to solve. Multi-pronged effort aimed at cancer biology, cancer imaging, and cancer therapy. Tissue foci include cancers of the breast, brain, pancreas, lung, and kidney.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
The goals of bioengineering strategies for targeted cancer therapies are (1) to deliver a high dose of an anticancer drug directly to a cancer tumor, (2) to enhance drug uptake by malignant cells, and (3) to minimize drug uptake by nonmalignant cells. Effective cancer-targeting therapies will require both passive- and active-targeting strategies and a thorough understanding of physiologic barriers to targeted drug delivery. Designing a targeted therapy includes the selection and optimization of a nanoparticle delivery vehicle for passive accumulation in tumors, a targeting moiety for active receptor-mediated uptake, and stimuli-responsive polymers for control of drug release. The future direction of cancer targeting is a combinatorial approach, in which targeting therapies are designed to use multiple-targeting strategies. The combinatorial approach will enable combination therapy for delivery of multiple drugs and dual ligand targeting to improve targeting specificity. Targeted cancer treatments in development and the new combinatorial approaches show promise for improving targeted anticancer drug delivery and improving treatment outcomes.
Cancer is a generic term for a large group of diseases that can affect any part of the body. Other terms used are malignant tumors and neoplasms. Metastases are the major cause of death from cancer. Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012.
About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world. Breast cancer, the most common tumour in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years. Lung cancer is one of the most aggressive tumors and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years. Colorectal cancer (of the colon and rectum), the most common malignant tumour if we group men and women together, presents an average survival rate of 50-55% five years after diagnosis, meaning that half the patients survive this form of cancer. Prostate cancer, today the most common tumour in men, has an increasingly favorable prognosis, with a global survival rate of 76%, which is higher in young adults. Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.
1. 6th Cancer Therapy Conference, December 01-03, 2016 in Baltimore, USA
2. 7th Cancer Therapy Conference, October 05-07, 2015, Dubai, UAE
3. 8th Euro Cancer Therapy Conference, November 03-05, 2015, Valencia, Spain
4. 9th Cancer Therapy Conference , November 02-04, 2015 Hyderabad, India
5. 11th Oncologists Conference, July 11-13, 2016 Kuala Lumpur, Malaysia
7. 2nd Synthetic Biology Conference, August 15-17, 2016 London, United Kingdom
10. Cancer Diagnostics Conference, June 13-15, 2016, Rome, Italy
11. European Cancer Congress, Vienna, Austria
12. European Breast Cancer Conference in 2016 (EBCC-10)
13. ESMO Preceptorship Meeting, Austria
14. 2015 Northeast Cancer Conference, Troy, NY
15. NCRI Cancer Conference, Liverpool
16. International Conference on Bioengineering and Biotechnology, Budapest, Hungary
17. 2015 Advances in Breast Cancer Research, Bellevue, Washington
18. International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts
19. New Horizons in Cancer Research Conference: Bringing Cancer Discoveries to Patients, Shanghai, P.R. China
20. EMBC 2016, Japan
21. UBEC 2015, Salt Lake City, UT
22. Chromatin and Epigenetics in Cancer, Atlanta, Georgia
23. Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, Orlando, Florida
24. 2016 World Cancer Congress, Paris
Relevant Organization and Associations:
1. European Society for Medical Oncology
2. European Society of Gynaecological Oncology
3. EuroPharm Forum
4. Friends of Cancer Research
5. American Cancer Society
6. National Cancer Institute
7. German Cancer Aid
8. Cancer Council Australia
9. Edinburgh Cancer Research Centre
10. World Cancer Research Fund, United Kingdom
4. Bristol-Myers Squibb
7. Merck & Co.
This page will be updated regularly.
This page was last updated on 12th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising